Skip Ribbon Commands
Skip to main content
Back to Search Results

A randomized, treatment open-label, dose-blinded parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy

The purpose of the study is to find out if the drug called “LNP023” is safe and has beneficial effects in people who have membranous nephropathy (MN) compared with rituximab. MN is a disease of the kidney that causes an increase in the amount of protein eliminated in the urine. The main objective of this research is to see whether taking LNP023 or rituximab for 6 months results in lower urine protein levels and to compare these two treatments in patients with MN.

Condition: Intervention: Phase:
Kidney Disease (Membranous Nephropathy) 1) LNP023 is an oral medication that inhibits Factor B (a key component of the alternative complement pathway) which may improve MN. 2) Rituximab belongs to a class of drugs called monoclonal antibodies. It binds to a protein called CD20 found on the surface of B-cells; B-cells are a group of white blood cells, which are part of the body`s defense system, and play a role in MN. This medicine is given as Infusion. II
Status: Open
Volunteers Required: Yes
Published Date: 12 October 2020

Term of Use/Disclaimer

All information provided within this web and mobile application is intended for general information and is provided on the understanding that no surgical and medical advice or recommendation is being rendered. Please do not disregard the professional advice of your physician.

Last updated on